TNC Featured Speakers

TNC Featured Speakers
Sunday, 28 June, 2020 


Wolfgang Grisold, MD, PhD, FAAN Ludwig Boltzmann Institute for Experimental und Clinical Traumatology, Vienna, Austria 
Title:  Toxic Neuropathies 

 

Toxic Neuropathies Toxic neuropathies have several causes and the classification goes far beyond the axonal and demyelinating type. In addition to the commonly considered targets for toxicity as the dorsal root ganglia, nerve and axons, also receptors , nerve ending and small fibers need to be considered. Also Ion channels and ionophores are sites of toxicity. The onset of toxicity can be acute, is usually delayed, but can also result in late effects, and is rarely also self propagating. The frequency of toxic neuropathy is not known, and in addition to commonly used industrial agents, heavy metals, drugs , recreational substances, also rare and nutritional neuropathies occur.

 


Ellen Lavoie Smith, PhD, MSN, RN, AOCN(R), FAAN University of Michigan, Ann Arbor, Michigan, USA 
Title: Chemotherapy-Induced Peripheral Neuropathy (CIPN): Characteristics, Patterns & Outcomes Across the Lifespan.

           

Dr. Smith will describe CIPN manifestations and outcomes in pediatric and adult populations, and provide recommendations for clinical practice and research.

Ellen M. Lavoie Smith, PhD, MSN, RN, AOCN®, FAAN, is a Professor and the PhD Program Director at the University of Michigan (UM) School of Nursing. Dr. Smith’s research is well recognized as pioneering and pivotal in identifying interventions for chemotherapy-induced peripheral neuropathy (CIPN), a life-altering complication of neurotoxic chemotherapy for which no known treatments have been discovered. Her research addresses the National Cancer Institute’s (NCI) goal to minimize cancer treatment-associated side effects and the priority recommendation outlined in the National Academy of Medicine’s Report on Pain in America regarding the need for non-opioid pain treatments. She has received independent extramural research funding from the National Institutes of Health (NIH) and foundation and industry sponsors. She was the principal investigator for a NCI-funded multi-site randomized placebo-controlled trial to test duloxetine as a treatment for painful CIPN. This groundbreaking research revealed duloxetine efficacy and the results were published in JAMA, Journal of the American Medical Association (2013). As a result, duloxetine is now the only treatment for painful CIPN recommended by the American Society of Clinical Oncology. She currently leads another NCI-funded Phase II-III trial to test duloxetine to prevention CIPN.



TNC Featured Speakers
Monday, 29 June, 2020 


Francesca Bartoini, PhD, Columbia University, New York, New York, USA 
Title:  Pathogenic role of tubulin post translational modifications in axon degeneration

        

Tubulin, its post-translational modifications, microtubule dynamics and stability play critical roles in neurons, including regulation of long-distance transport, microtubule severing, Ca2+ homeostasis and mitochondria energetics. Each of these functions provides a potential mechanism underlying axon degeneration. Herein, we report that in sensory neurons the CIPN inducing drug bortezomib causes axonopathy and disrupted mitochondria motility by increasing delta 2 tubulin, the only irreversible tubulin modification and marker of hyperstable microtubules. Our data provide a new paradigm for the risk associated with enhanced tubulin longevity in the onset of peripheral neuropathy and offer the unexplored potential for targeting the enzymes involved in this tubulin modification in drug therapies aimed at preventing axonal injury observed in CIPN and possibly other types of related neuropathies.


Andreas Argyriou, MD, DSc Saint Andrew's General Hospital of patras, Patras, Greece
Title: Natural History of Chemotherapy-Induced Peripheral Neurotoxicitiy (CIPN)

         

Chemotherapy-induced peripheral neurotoxicity (CIPN) is a potentially dose-limiting side effect of several commonly used cytotoxic chemotherapy agents. CIPN remains a significant clinical problem but also a very challenging area of research. A large, international, multicentre study (ICAVS study) is ready to be launched from the Toxic Neuropathy Consortium in order to ascertain in detail the natural history of CIPN.

 

Thank you to our 2019 PNS Sponsors!